<DOC>
	<DOCNO>NCT00352066</DOCNO>
	<brief_summary>The aim study see apricitabine tipranavir affect level blood ( pharmacokinetic interaction ) dose together .</brief_summary>
	<brief_title>Pharmacokinetics Apricitabine Tipranavir When Dosed Alone Together</brief_title>
	<detailed_description>Apricitabine new NRTI development treatment drug resistant HIV . Tipranavir recently license protease inhibitor treatment drug resistant HIV . Tipranavir affect plasma concentration drug use together tipranavir . This study examine whether pharmacokinetics apricitabine change dose together tipranavir compare apricitabine alone . Also , pharmacokinetics tipranavir examine steady state dose alone dose together apricitabine . Information safety tolerability two drug dose together also obtain .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tipranavir</mesh_term>
	<criteria>healthy male 1840 year old nonsmoker clinically significant medical history current relevant previous medical history significance hepatitis B , hepatitis C , HIV positive current use prescription OTC medication use illicit substance alcohol ( &gt; 14 drinks/week )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>anti-retroviral therapy</keyword>
	<keyword>nucleoside analogue</keyword>
	<keyword>reverse transcriptase</keyword>
	<keyword>apricitabine</keyword>
	<keyword>tipranavir</keyword>
	<keyword>bioequivalence</keyword>
	<keyword>drug-drug interaction</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>